




公告日期	2026/9/2
異動類別	藥品變更
異動原因	年度招標
異動描述	Epoetin α inj 2000IU/0.5mL/syrg (Eprex[®])宜保利血注射液因年度招標異動，改以Epoetin β inj 外觀 2000IU/0.3mL/syrg (Recormon[®])容可曼針筒裝注射劑替代。 舊品用罄，啟用新品。

異動內容		
	舊藥品	新藥品
料號	324659	302855
學名	Epoetin α	Epoetin β
商品名	Eprex	Recormon
中文名	宜保利血注射液	容可曼針筒裝注射劑
主成份及含量	2000IU/0.5mL/syrg	2000IU/0.3mL/syrg
製造廠名稱	Cilag AG (Cilag)	Roche Diagnostics GmbH (羅氏)
產地	瑞士	德國
健保代碼	KC00582212	KC00876212
外觀/圖檔		
用法	皮下注射	

小孩劑量	Anemia in chronic kidney disease (ON dialysis):Initial dose:Infants, Children, and Adolescents ?16 years: IV, SubQ: 50 units/kg/dose 3 times weekly Adolescents >16 years: IV, SubQ: 50 to 100 units/kg/dose 3 times weekly	Anemia, CKD related: 1~17 years: <u>Initial:</u> Max: 720 IU/kg IV/SC weekly /I/: 40 IU/kg tiw. After 4 wks, may ↑ dose to 80 IU/kg tiw. May further ↑ dose by 20 IU/kg/dose q4w if necessary SC: 20 IU/kg tiw or 60 IU/kg divided into 7 daily doses. May further ↑ dose by 60 IU/kg/week q4w if necessary <u>Maintenance:</u> After reaching Hb target, ↓ weekly dose 50 % of the previously administered dose and titrate q1~2w until stable Hb response is achieved
成人劑量	CKD patients ON dialysis: IV, SUBQ: Initial dose: 50 to 100 units/kg 3 times a week. Anemia due to chemotherapy in cancer patients:SUBQ: Initial dose: 150 units/kg 3 times a week or 40,000 units once weekly	Anemia, CKD related: <u>Initial:</u> Max: 720 IU/kg IV/SC weekly /I/: 40 IU/kg tiw. After 4 wks, may ↑ dose to 80 IU/kg tiw. May further ↑ dose by 20 IU/kg/dose q4w if necessary SC: 20 IU/kg tiw or 60 IU/kg divided into 7 daily doses. May further ↑ dose by 60 IU/kg/week q4w if necessary <u>Maintenance:</u> After reaching Hb target, ↓ weekly dose 50 % of the previously administered dose and titrate q1~2w until stable Hb response is achieved Anemia, chemotherapy related: SC: <u>Initial:</u> 450 IU/kg qw or divided into tiw or 7 daily doses; Max: 60,000 IU/wk <u>After 4 wks:</u> adjust initial dose based on change in Hb: If Hb ↑ 1~2 g/dL: continue initial dose If Hb ↑ <1 g/dL: consider doubling initial dose (Max: 60,000 IU/wk) If Hb ↑ >2 g/dL: ↓ dose by 25~50 % If Hb >12 g/dL and ?13 g/dL: ↓ dose by 25~50 % If Hb >13 g/dL: hold until Hb ?12 g/dL, reinitiate at ~25% of previous dose <u>Maintenance:</u> After reaching Hb target, ↓ dose by 25~50 % to maintain target Hb level
副作用		